Fresenius SE KGaA (BRSE:000332902) - Stock Price, News & Analysis

000332902 Stock Overview

A health care company, provides products and services for chronically ill patients.

000332902 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	4/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 63.5% below our estimate of its fair value

Earnings are forecast to grow 23.72% per year

Earnings grew by 29.9% over the past year

Risk Analysis

Interest payments are not well covered by earnings

Fresenius SE & Co. KGaA Competitors

Sonova Holding

SWX:SOON

CHF 17.9b

Straumann Holding

SWX:STMN

CHF 21.4b

Galenica

SWX:GALE

CHF 3.7b

Alcon

SWX:ALC

CHF 41.4b

Price History & Performance

Summary of all time highs, changes and price drops for Fresenius SE KGaA
Historical stock prices
Current Share Price	€53.06
52 Week High	€0
52 Week Low	€0
Beta	1.07
11 Month Change	0%
3 Month Change	0%
1 Year Change	0%
33 Year Change	0%
5 Year Change	0.019%
Change since IPO	7.82%

Recent updates

Shareholder Returns

	000332902	CH Healthcare	CH Market
7D	0%	-1.3%	1.3%
1Y	0%	2.1%	9.4%

Return vs Industry: 000332902 matched the Swiss Healthcare industry which returned 0.2% over the past year.

Return vs Market: 000332902 underperformed the Swiss Market which returned 7.5% over the past year.

Price Volatility

Is 000332902's price volatile compared to industry and market?
000332902 volatility
000332902 Average Weekly Movement	0%
Healthcare Industry Average Movement	4.4%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	6.7%
10% least volatile stocks in CH Market	1.5%

Stable Share Price: 000332902 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 000332902's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1912	175,771	Michael Sen	www.fresenius.com

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Fresenius SE & Co. KGaA Fundamentals Summary

How do Fresenius SE KGaA's earnings and revenue compare to its market cap?
000332902 fundamental statistics
Market cap	CHF 17.75b
Earnings (TTM)	CHF 682.29m
Revenue (TTM)	CHF 21.42b

26.0x

P/E Ratio

0.8x

P/S Ratio

Is 000332902 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
000332902 income statement (TTM)
Revenue	€22.63b
Cost of Revenue	€17.41b
Gross Profit	€5.23b
Other Expenses	€4.51b
Earnings	€721.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 06, 2024

Earnings per share (EPS)	1.28
Gross Margin	23.09%
Net Profit Margin	3.19%
Debt/Equity Ratio	61.2%

How did 000332902 perform over the long term?

See historical performance and comparison

000332902 Stock Overview

Rewards

Risk Analysis

Fresenius SE & Co. KGaA Competitors

SWX:SOON

CHF 17.9b

SWX:STMN

CHF 21.4b

SWX:GALE

CHF 3.7b

SWX:ALC

CHF 41.4b

Price History & Performance

Recent News & Updates

Second quarter 2024 earnings released: EPS: €0.34 (vs €0.21 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

New major risk - Financial position

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Recent updates

Second quarter 2024 earnings released: EPS: €0.34 (vs €0.21 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

New major risk - Financial position

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

German Fresenius Reportedly Seeks to Sell Vamed Reha

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.14 (vs €0.68 in 2Q 2022)

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings released: EPS: €0.61 (vs €0.74 in 1Q 2022)

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: EPS: €2.44 (vs €3.26 in FY 2021)

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Brookfield Reportedly Drops Out of Race to Buy Healius

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Second quarter 2022 earnings released: EPS: €0.68 (vs €0.84 in 2Q 2021)

Healius Reportedly Launches Day Surgery Sale Process

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Upcoming dividend of €0.92 per share

First quarter 2022 earnings released: EPS: €0.74 (vs €0.78 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Fresenius SE & Co. KGaA Provides Earnings Guidance for the Year 2022

Third quarter 2021 earnings released: EPS €0.74 (vs €0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.84 (vs €0.74 in 2Q 2020)

Upcoming dividend of €0.88 per share

First quarter 2021 earnings released: EPS €0.78 (vs €0.82 in 1Q 2020)

Full year 2020 earnings released: EPS €3.06 (vs €3.38 in FY 2019)

Fresenius SE & Co. KGaA to Report Q1, 2021 Results on May 07, 2021

Fresenius SE & Co. KGaA, Annual General Meeting, May 21, 2021

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Shareholder Returns

Price Volatility

About the Company

Fresenius SE & Co. KGaA Fundamentals Summary

26.0x

0.8x

Earnings & Revenue